DNTH

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Dianthus Therapeutics Inc.

NASDAQ | DNTH

39.49

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 18, 2025)

$1.55B

Market Cap

-

P/E Ratio

-3.27

EPS

$39.70

52 Week High

$13.37

52 Week Low

HEALTHCARE

Sector

DNTH Chart

Recent Chart
Price Action

DNTH Technicals

Tags:

DNTH Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $6.2M
Total Revenue $6.2M
Cost Of Revenue $412K
Costof Goods And Services Sold $412K
Operating Income -$102M
Selling General And Administrative $25M
Research And Development $83M
Operating Expenses $108M
Investment Income Net -
Net Interest Income $17M
Interest Income $17M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $412K
Income Before Tax -$85M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$85M
Comprehensive Income Net Of Tax -
Ebit -$102M
Ebitda -$101M
Net Income -$85M

Revenue & Profitability

Earnings Performance

DNTH Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $374M
Total Current Assets $281M
Cash And Cash Equivalents At Carrying Value $23M
Cash And Short Term Investments $23M
Inventory -
Current Net Receivables $807K
Total Non Current Assets $93M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $82M
Short Term Investments $252M
Other Current Assets $4.9M
Other Non Current Assets -
Total Liabilities $22M
Total Current Liabilities $18M
Current Accounts Payable $4.6M
Deferred Revenue -
Current Debt -
Short Term Debt $320K
Total Non Current Liabilities $3.1M
Capital Lease Obligations $1.5M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $1.5M
Other Current Liabilities $13M
Other Non Current Liabilities -
Total Shareholder Equity $352M
Treasury Stock -
Retained Earnings -$174M
Common Stock $31K
Common Stock Shares Outstanding $33M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$78M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $412K
Capital Expenditures $105K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$287M
Cashflow From Financing $256M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$85M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $6.2M
Total Revenue $6.2M
Cost Of Revenue $412K
Costof Goods And Services Sold $412K
Operating Income -$102M
Selling General And Administrative $25M
Research And Development $83M
Operating Expenses $108M
Investment Income Net -
Net Interest Income $17M
Interest Income $17M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $412K
Income Before Tax -$85M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$85M
Comprehensive Income Net Of Tax -
Ebit -$102M
Ebitda -$101M
Net Income -$85M

DNTH News

DNTH Profile

Dianthus Therapeutics Inc. Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Dianthus Therapeutics, Inc. is a New York-based clinical-stage biotechnology firm focused on advancing innovative monoclonal antibody therapies targeting severe autoimmune and inflammatory diseases. With a robust pipeline, the company aims to address unmet medical needs through its proprietary antibody drug development programs. As it progresses through clinical trials, Dianthus positions itself as a potential leader in precision medicine for challenging health conditions, appealing to institutional investors seeking opportunities in cutting-edge biopharmaceutical solutions.

INTC
+28.93%
$32.10
DVLT
+16.60%
$0.39
CGBS
-39.47%
$0.03
SNAP
+3.23%
$7.99
AERT
+58.84%
$0.90
ADAP
+27.84%
$0.10
GPUS
+28.56%
$0.52
APVO
+37.48%
$1.93
BITF
+11.31%
$3.39
ATCH
-3.39%
$1.56
NEHC
-4.00%
$0.45
NVDA
+2.92%
$175.27
TPIC
-45.91%
$0.12
PLUG
+4.49%
$2.08
AXDX
-61.36%
$0.03
CDLX
+64.40%
$2.35
ETNB
+85.21%
$14.96
LASE
+33.52%
$3.73
RGTI
+16.16%
$25.54
LYT
-16.77%
$0.09
GRAB
+3.34%
$6.30
KDLY
-4.66%
$1.43
AMD
-3.10%
$154.22
CJET
+2.15%
$0.09
MULN
-6.96%
$0.06
VHAI
0.00%
$0.00
RMBL
+60.50%
$3.21
TSLA
-0.25%
$424.76
AAL
+0.76%
$12.57
QBTS
+4.79%
$23.62
ADD
-25.47%
$0.05
BMNR
+6.16%
$60.59
SRM
+53.27%
$10.30
NIO
-0.06%
$7.44
BINI
-15.47%
$0.05
SOUN
+1.71%
$15.37
PLTR
+3.67%
$174.52
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
WLGS
-5.57%
$0.04
NFE
+14.87%
$2.48
RAYA
-4.69%
$0.04
RR
+10.73%
$4.40
ETWO
0.00%
$3.30
CLSK
+13.25%
$12.95
MARA
+6.63%
$18.48
QS
+11.20%
$11.41
AFMD
-34.94%
$0.18
PBM
+32.25%
$4.92
NVNI
+22.95%
$0.98
SMCI
-0.02%
$44.90
QUBT
+3.67%
$18.36
BEEM
+18.47%
$2.99
BURU
+0.14%
$0.13
IXHL
+1.25%
$0.53
IONQ
+7.02%
$70.04
DNN
-1.18%
$2.50
F
+0.08%
$11.67
AQB
+17.98%
$1.34
SOFI
+1.30%
$27.49
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
CDE
-1.65%
$16.00
BCDA
-23.12%
$1.18
UEC
-3.10%
$11.86
BBD
-1.20%
$3.27
ONDS
+2.66%
$6.26
BTG
-0.92%
$4.29
HOOD
+3.04%
$122.24
JOBY
+3.75%
$14.69
LDI
-11.73%
$4.02
AMZN
+0.25%
$232.21
CIFR
-4.02%
$11.88
QSI
+24.20%
$1.56
AAPL
-0.26%
$238.34
SBET
+6.69%
$18.26
LAWR
+37.17%
$2.77
IONZ
-10.18%
$4.31
RCAT
-7.41%
$10.43
RXRX
+4.03%
$4.89
NOK
+1.06%
$4.75
ACHR
+2.16%
$9.19
ORIS
+9.67%
$0.15
OPI
-34.61%
$0.37
ZAPP
-46.30%
$0.15
GOOGL
+0.27%
$250.20
ADGM
-3.68%
$1.57
AIRE
-4.00%
$1.19
NVO
+6.30%
$61.87
NAKA
-1.04%
$1.41
CAN
+1.86%
$0.82
ORBS
+21.59%
$13.20
BTBT
+4.45%
$3.16
YAAS
-6.49%
$0.06
TLRY
+2.52%
$1.22
REPL
-41.94%
$3.31
ORCL
-0.48%
$299.95
ABEV
-0.84%
$2.34
BABA
-2.29%
$162.36
RZLV
-1.64%
$6.99
INTC
+28.93%
$32.10
DVLT
+16.60%
$0.39
CGBS
-39.47%
$0.03
SNAP
+3.23%
$7.99
AERT
+58.84%
$0.90
ADAP
+27.84%
$0.10
GPUS
+28.56%
$0.52
APVO
+37.48%
$1.93
BITF
+11.31%
$3.39
ATCH
-3.39%
$1.56
NEHC
-4.00%
$0.45
NVDA
+2.92%
$175.27
TPIC
-45.91%
$0.12
PLUG
+4.49%
$2.08
AXDX
-61.36%
$0.03
CDLX
+64.40%
$2.35
ETNB
+85.21%
$14.96
LASE
+33.52%
$3.73
RGTI
+16.16%
$25.54
LYT
-16.77%
$0.09
GRAB
+3.34%
$6.30
KDLY
-4.66%
$1.43
AMD
-3.10%
$154.22
CJET
+2.15%
$0.09
MULN
-6.96%
$0.06
VHAI
0.00%
$0.00
RMBL
+60.50%
$3.21
TSLA
-0.25%
$424.76
AAL
+0.76%
$12.57
QBTS
+4.79%
$23.62
ADD
-25.47%
$0.05
BMNR
+6.16%
$60.59
SRM
+53.27%
$10.30
NIO
-0.06%
$7.44
BINI
-15.47%
$0.05
SOUN
+1.71%
$15.37
PLTR
+3.67%
$174.52
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
WLGS
-5.57%
$0.04
NFE
+14.87%
$2.48
RAYA
-4.69%
$0.04
RR
+10.73%
$4.40
ETWO
0.00%
$3.30
CLSK
+13.25%
$12.95
MARA
+6.63%
$18.48
QS
+11.20%
$11.41
AFMD
-34.94%
$0.18
PBM
+32.25%
$4.92
NVNI
+22.95%
$0.98
SMCI
-0.02%
$44.90
QUBT
+3.67%
$18.36
BEEM
+18.47%
$2.99
BURU
+0.14%
$0.13
IXHL
+1.25%
$0.53
IONQ
+7.02%
$70.04
DNN
-1.18%
$2.50
F
+0.08%
$11.67
AQB
+17.98%
$1.34
SOFI
+1.30%
$27.49
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
CDE
-1.65%
$16.00
BCDA
-23.12%
$1.18
UEC
-3.10%
$11.86
BBD
-1.20%
$3.27
ONDS
+2.66%
$6.26
BTG
-0.92%
$4.29
HOOD
+3.04%
$122.24
JOBY
+3.75%
$14.69
LDI
-11.73%
$4.02
AMZN
+0.25%
$232.21
CIFR
-4.02%
$11.88
QSI
+24.20%
$1.56
AAPL
-0.26%
$238.34
SBET
+6.69%
$18.26
LAWR
+37.17%
$2.77
IONZ
-10.18%
$4.31
RCAT
-7.41%
$10.43
RXRX
+4.03%
$4.89
NOK
+1.06%
$4.75
ACHR
+2.16%
$9.19
ORIS
+9.67%
$0.15
OPI
-34.61%
$0.37
ZAPP
-46.30%
$0.15
GOOGL
+0.27%
$250.20
ADGM
-3.68%
$1.57
AIRE
-4.00%
$1.19
NVO
+6.30%
$61.87
NAKA
-1.04%
$1.41
CAN
+1.86%
$0.82
ORBS
+21.59%
$13.20
BTBT
+4.45%
$3.16
YAAS
-6.49%
$0.06
TLRY
+2.52%
$1.22
REPL
-41.94%
$3.31
ORCL
-0.48%
$299.95
ABEV
-0.84%
$2.34
BABA
-2.29%
$162.36
RZLV
-1.64%
$6.99
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.